Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news, and so much more. We look forward to having you join our Share the Science audience for this exciting and dynamic series!
Timothy Nelson, MD, PhD, discusses hypoplastic left heart syndrome (HLHS) and the use of regenerative medicine to make the heart stronger.
Dr. Nelson, the director of Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, will discuss the use of regenerative medicine in hypoplastic left heart syndrome (HLHS), a rare congenital heart defect. One of the clinical trials at the Todd and Karen Wanek Family Program for HLHS uses stem cells collected from umbilical cord blood. The umbilical cord blood cells are processed in a specific manner in order to create highly concentrated stem cells that are injected into the heart at the time of the baby’s second open heart surgery.
The HLHS program has also recently created the HLHS consortium, a network of institutions that are participating in HLHS research. The consortium makes it easier for patients to participate in the overall research, including the umbilical cord blood collection, no matter their location.
You will learn:
- The importance of banking umbilical cord blood for babies with HLHS
- What makes Mayo Clinic’s Todd and Karen Wanek Family Program for HLHS unique when it comes to umbilical cord blood banking
- Details about the clinical trial using umbilical cord blood for babies with HLHS
- How HLHS research at Mayo Clinic’s HLHS program is changing the future for HLHS individuals
Dr. Timothy Nelson is an associate professor of medicine and pharmacology, the director of the Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, and the medical director of the Regenerative Medicine Consult Service.
Dr. Nelson’s research work is focused on cardiovascular regeneration using bioengineered stem cells to improve the ability to discover, diagnose, and ultimately treat mechanisms of degenerative diseases such as cardiomyopathy. His lab looks to identify better ways to predict the onset and progression of genetic disease within the cell culture model system in the laboratory without the need for probing the patient beyond the initial tissue collection. Building on expertise of embryology and cardiac developmental biology to study lineage specific defects in pluripotent stem cells, his research program is striving to translate innovative applications based on iPS technology into clinical applications in human diseases. This individualized platform allows for pharmacological-based screening efforts to identify novel therapeutic targets using patient-specific stem cell and differentiated derivatives.
Dr. Nelson earned his PhD and MD from the Medical College of Wisconsin in Milwaukee. He completed his residency and fellowship work at Mayo Clinic in Rochester, MN, and has published more than 70 journal articles.